NASDAQ:AKBA

Akebia Therapeutics (AKBA) Stock Forecast, Price & News

$1.10

+0.01 (+0.92%)

(As of 06/2/2023 ET)

Compare

Today's Range: $1.07
▼
$1.17
50-Day Range: $0.51
▼
$1.43
52-Week Range: $0.24
▼
$1.63

Volume: 1.77 million shs
Average Volume: 2.38 million shs
Market Capitalization: $204.52 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.00

Akebia Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 81.8% Upside
$2.00 Price Target
Short Interest: Healthy
2.19% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.35
Upright™ Environmental Score
News Sentiment: -0.13
Based on 12 Articles This Week
Insider Trading: Selling Shares
$261,587 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.28) to ($0.16) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

287th out of 983 stocks

Pharmaceutical Preparations Industry

126th out of 486 stocks

3.3

Analyst's Opinion

Consensus Rating
Akebia Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $2.00, Akebia Therapeutics has a forecasted upside of 81.8% from its current price of $1.10.
Amount of Analyst Coverage
Akebia Therapeutics has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.19% of the outstanding shares of Akebia Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Akebia Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Akebia Therapeutics has recently decreased by 9.56%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Akebia Therapeutics does not currently pay a dividend.
Dividend Growth
Akebia Therapeutics does not have a long track record of dividend growth.

4.1

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Akebia Therapeutics has received a 57.59% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Various other types of medication (V)" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Akebia Therapeutics is -1.35.

1.6

News and Social Media Coverage

News Sentiment
Akebia Therapeutics has a news sentiment score of -0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Akebia Therapeutics this week, compared to 2 articles on an average week.
Search Interest
21 people have searched for AKBA on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Akebia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $261,587.00 in company stock.
Percentage Held by Insiders
Only 3.68% of the stock of Akebia Therapeutics is held by insiders.
Percentage Held by Institutions
Only 28.13% of the stock of Akebia Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Akebia Therapeutics are expected to grow in the coming year, from ($0.28) to ($0.16) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Akebia Therapeutics is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Akebia Therapeutics is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Akebia Therapeutics (NASDAQ:AKBA) Stock

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Receive AKBA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKBA Stock News Headlines

June 2, 2023 | msn.com

Akebia settles last patent lawsuit related to kidney disease therapy

June 2, 2023 | finance.yahoo.com

Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?

June 3, 2023 | Stansberry Research (Ad)

Why 2023 Could Kick Off a "Cash Frenzy" in Stocks

But the analyst who called the Lehman Collapse says to expect a "Cash Frenzy" instead.

June 2, 2023 | finance.yahoo.com

All You Need to Know About Akebia Therapeutics (AKBA) Rating Upgrade to Buy

May 31, 2023 | msn.com

Piper Sandler Upgrades Akebia Therapeutics (AKBA)

May 31, 2023 | americanbankingnews.com

Akebia Therapeutics (NASDAQ:AKBA) Upgraded to Overweight by Piper Sandler

May 30, 2023 | seekingalpha.com

Akebia says FDA denied appeal for kidney disease candidate

May 30, 2023 | msn.com

Akebia Therapeutics Soars on Way Forward for Vadadustat in the U.S.

June 3, 2023 | Investor Place Media (Ad)

Biden To Unleash "Choke Point" Operation On America?

Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.

May 30, 2023 | markets.businessinsider.com

Akebia: FDA Denies Formal Dispute Resolution, But Provides Company Path Forward For Vadadustat

May 30, 2023 | finance.yahoo.com

FDA Provides Akebia Therapeutics a Path Forward for Vadadustat

May 29, 2023 | americanbankingnews.com

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Sees Significant Drop in Short Interest

May 28, 2023 | americanbankingnews.com

Insider Selling: Akebia Therapeutics, Inc. (NASDAQ:AKBA) SVP Sells $77,086.92 in Stock

May 27, 2023 | americanbankingnews.com

Akebia Therapeutics, Inc. (NASDAQ:AKBA) COO Michel Dahan Sells 95,478 Shares

May 27, 2023 | americanbankingnews.com

Akebia Therapeutics Sees Unusually Large Options Volume (NASDAQ:AKBA)

May 26, 2023 | msn.com

HC Wainwright & Co. Reiterates Akebia Therapeutics (AKBA) Neutral Recommendation

May 26, 2023 | markets.businessinsider.com

Analyst Ratings for Akebia Therapeutics

May 26, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Their Hold Rating for Akebia Therapeutics (AKBA)

May 26, 2023 | msn.com

The Latest Analyst Ratings for Akebia Therapeutics

May 25, 2023 | finance.yahoo.com

Akebia Therapeutics Enters into License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG for the Commercialization of Vafseo® for the Treatment of Anemia associated with CKD in Europe and Australia

May 23, 2023 | finance.yahoo.com

Why Shares of Akebia Therapeutics Were Up Tuesday

May 23, 2023 | markets.businessinsider.com

These 14 Biotech Stocks Hit New Highs, Did You Get In Early?

May 23, 2023 | seekingalpha.com

Akebia Therapeutics regains Nasdaq compliance

May 22, 2023 | finance.yahoo.com

Akebia Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 22, 2023 | seekingalpha.com

Akebia Therapeutics wins UK approval of vadadustat for CKD anemia

May 22, 2023 | markets.businessinsider.com

Akebia Therapeutics Announces UK MHRA Marketing Authorization For Vafseo

May 22, 2023 | msn.com

Akebia Therapeutics's Return On Capital Employed Overview

See More Headlines

AKBA Price History

30 days | 90 days | 365 days | Advanced Chart

AKBA Company Calendar

Last Earnings: 3/09/2023
Today: 6/03/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AKBA
CUSIP: N/A
CIK: 1517022
Web: www.akebia.com
Phone: (617) 871-2098
Fax: 617-871-2099
Employees: 426
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $2.00
High Stock Price Forecast: $2.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +81.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.31)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-92,560,000.00
Net Margins: -20.79%
Pretax Margin: -20.79%
Return on Equity: -235.17%
Return on Assets: -10.55%

Debt

Debt-to-Equity Ratio: 3.65
Current Ratio: 1.46
Quick Ratio: 1.21

Sales & Book Value

Annual Sales: $271.03 million
Price / Sales: 0.75
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.08) per share
Price / Book: -13.75

Miscellaneous

Outstanding Shares: 185,928,000
Free Float: 179,086,000
Market Cap: $204.52 million
Optionable: Optionable
Beta: 0.73

Key Executives

John P. Butler
President, Chief Executive Officer & Director

Michel Dahan
Chief Operating Officer & Senior Vice President

David A. Spellman
Treasurer, Chief Financial & Accounting Officer

Steven K. Burke
Chief Medical Officer & SVP-Research & Development

Michael Rabinowitz
Vice President-Research

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AKBA Stock - Frequently Asked Questions

Should I buy or sell Akebia Therapeutics stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AKBA shares.
View AKBA analyst ratings or view top-rated stocks.
What is Akebia Therapeutics' stock price forecast for 2023?: 2 Wall Street research analysts have issued 1 year target prices for Akebia Therapeutics' stock. Their AKBA share price forecasts range from $2.00 to $2.00. On average, they anticipate the company's stock price to reach $2.00 in the next year. This suggests a possible upside of 81.8% from the stock's current price.
View analysts price targets for AKBA or view top-rated stocks among Wall Street analysts.
How have AKBA shares performed in 2023?: Akebia Therapeutics' stock was trading at $0.5770 at the beginning of 2023. Since then, AKBA stock has increased by 90.6% and is now trading at $1.10.
View the best growth stocks for 2023 here.
Are investors shorting Akebia Therapeutics?: Akebia Therapeutics saw a decrease in short interest in May. As of May 15th, there was short interest totaling 4,070,000 shares, a decrease of 9.6% from the April 30th total of 4,500,000 shares. Based on an average trading volume of 1,720,000 shares, the short-interest ratio is currently 2.4 days.
View Akebia Therapeutics' Short Interest.
When is Akebia Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our AKBA earnings forecast.
How were Akebia Therapeutics' earnings last quarter?: Akebia Therapeutics, Inc. (NASDAQ:AKBA) posted its earnings results on Thursday, March, 9th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.10. The biopharmaceutical company earned $55.18 million during the quarter, compared to analysts' expectations of $48.35 million. Akebia Therapeutics had a negative net margin of 20.79% and a negative trailing twelve-month return on equity of 235.17%.
What is John Butler's approval rating as Akebia Therapeutics' CEO?: 28 employees have rated Akebia Therapeutics Chief Executive Officer John Butler on Glassdoor.com. John Butler has an approval rating of 97% among the company's employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Akebia Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T).
What is Akebia Therapeutics' stock symbol?: Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."
Who are Akebia Therapeutics' major shareholders?: Akebia Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Alerce Investment Management L.P. (8.72%), BlackRock Inc. (1.45%), Renaissance Technologies LLC (1.26%), State Street Corp (0.37%), Connor Clark & Lunn Investment Management Ltd. (0.16%) and Victory Capital Management Inc. (0.14%). Insiders that own company stock include David A Spellman, John P Butler, Maxine Gowen, Michel Dahan, Nicole R Hadas, Steven C Gilman, Steven C Gilman, Steven Keith Burke and Violetta Cotreau.
View institutional ownership trends.
How do I buy shares of Akebia Therapeutics?: Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Akebia Therapeutics' stock price today?: One share of AKBA stock can currently be purchased for approximately $1.10.
How much money does Akebia Therapeutics make?: Akebia Therapeutics (NASDAQ:AKBA) has a market capitalization of $204.52 million and generates $271.03 million in revenue each year. The biopharmaceutical company earns $-92,560,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis.
How many employees does Akebia Therapeutics have?: The company employs 426 workers across the globe.
How can I contact Akebia Therapeutics?: Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The official website for the company is www.akebia.com. The biopharmaceutical company can be reached via phone at (617) 871-2098, via email at ir@akebia.com, or via fax at 617-871-2099.

This page (NASDAQ:AKBA) was last updated on 6/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial